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Background: Integrative medicine (IM) provides patient-centered care and addresses the full range of physical,
emotional, mental, social, spiritual, and environmental influences that affect a person’s health. IM is a “whole
systems” approach that employs multiple modalities as opposed to an isolated complementary therapy. Thus,
studying outcomes of IM is more challenging than evaluating an isolated intervention. Practice-based research
networks (PBRNs) allow for clinicians/investigators at multiple diverse sites using common methodology to
pool their data, increase participant sample size and increase generalizability of results. To conduct real-world,
practice-based research, the Bravewell Collaborative founded BraveNet in 2007 as the first national integrative
medicine PBRN.
Methods and design: Patients Receiving Integrative Medicine Effectiveness Registry (PRIMIER) is a prospective,
non-randomized, observational evaluation conducted at fourteen clinical sites. Participants receive a non-standardized,
personalized, multimodal IM approach for various medical conditions. Using the REDCap electronic platform,
an anticipated 10,000 study participants will complete patient-reported outcome measures including Patient
Reported Outcomes Measurement Information System (PROMIS)-29, Perceived Stress Scale-4, and the Patient
Activation Measure at baseline, 2, 4, 6, 12, 18 and 24 months. Extractions from participants’ electronic health
records include IM services received, as well as ICD diagnostic codes, and CPT billing codes associated with
each IM visit. Repeated-measures analyses will be performed on data to assess change from baseline through
24 months with planned subgroup analyses to include specific clinical population and specific IM intervention
or combinations.
Discussion: As the PRIMIER registry grows, we anticipate that our results would provide an indication of the
promise of PBRN research efforts in IM. Analyses will incorporate a large sample of participants and an expected 10-year
observation period and will provide the ability to evaluate the effect of IM on outcomes for specific clinical populations
and specific IM interventions or combinations. As such, PRIMIER will serve as a national platform for future evaluations
of IM best practices.
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Integrative medicine (IM) provides patient-centered care
and addresses the full range of physical, emotional,
mental, social, spiritual, and environmental influences
that affect a person’s health [1]. Employing a personalized
strategy that considers the patient’s unique conditions,
needs, and circumstances, IM uses the most appropriate
interventions from an array of scientific disciplines to heal
illness and help people regain and maintain optimal health
[1]. Because IM is a “whole systems” approach that
employs multiple modalities in concert as opposed
to an isolated complementary therapy, studying outcomes
is more challenging than evaluating an isolated pharma-
ceutical or botanical intervention [2].
“Patient-reported outcome” (PRO) measures are health
data provided directly by patients, rather than outcomes
that reflect the assessment of an investigator or clinician,
as typically seen in clinical research. A PRO is an individ-
ual patient’s self-reported assessment of their feelings or
functions as they are dealing with diseases or conditions,
and this assessment has important implications both in
clinical practice and in research. PRO data are especially
important in evaluating the effectiveness of health care for
chronic conditions, where a primary goal of treatment is
to improve patients’ function and to reduce symptoms
associated with the condition [3, 4]. Criticisms of the use
of PROs in clinical research have been the wide range
of instruments used, often to measure similar outcomes,
and the lack of standardization between outcome mea-
sures [4]. The recent development [5] of the NIH-funded
Patient-Reported Outcomes Measurement Information
System (PROMIS) suite of item banks and short forms for
assessing health outcome domains related to quality of life
and chronic conditions has been cited by researchers as a
viable solution to these concerns [4, 6].
Single-site studies in IM are generally too small to iden-
tify differences in outcomes across sociodemographic or
clinical subgroups. Multi-institutional scientific networks
are able to recruit large numbers of participants for
observational and interventional trials. Practice-based
research networks (PBRNs) allow for clinicians/investiga-
tors at multiple diverse sites using common methodology
and a single coordinating/data analysis center to pool their
data as well as increase generalizability of results. By col-
lecting data in the context of patients receiving their
clinical care, the results are more reflective of “real world”
outcomes. Given the growth of the number of clinics
providing IM [7] and the resulting need for these clinics
to conduct real-world, practice-based research, the Brave-
well Collaborative founded BraveNet in 2007 as the first
national IM PBRN. BraveNet, a registered PBRN with the
Agency for Healthcare Research and Quality (AHRQ),
was established with the intent that it would provide
data on IM’s use, effectiveness, safety, costs, and patientsatisfaction. As of early 2015, BraveNet consists of 14
IM clinics that have robust patient populations as well
as strong research capabilities.
In this description of our study protocol, we describe
the approach taken to conduct a multi-site prospective
observational cohort study of PROs in our network of
IM clinics. The Patients Receiving Integrative Medicine
Interventions Effectiveness Registry (PRIMIER) provides
an opportunity to better understand which IM interven-
tions patients are receiving, and how these interventions
impact both clinical measures and PROs, such as quality
of life. Because randomized controlled trials can only
examine one or two specific interventions for a narrowly
defined condition—and because IM often uses highly
individualized combinations of interventions to treat
multiple conditions simultaneously—the evidence base
to support clinical decision making in IM is not progres-
sing rapidly enough to address the widespread use of this
approach in our health care system [8]. There have been a
few attempts to conduct randomized trials of IM interven-
tions. However, these have been limited by: small sample
size and inadequate power [9]; generalizability and resource
intensiveness [10]; and retention challenges potentially re-
lated to participant dissatisfaction with being randomized
to the non-IM arm, as well as limited follow-up [11].
Methods
Overview
In 2013, BraveNet created and launched PRIMIER (Patients
Receiving Integrative Medicine Interventions Effectiveness
Registry), a multi-institutional project designed to uniformly
collect PROs and extract electronic health record (EHR)
data into a large national registry. The goal of PRIMIER is
to provide a framework that can be used for evidence-based
practice, discernment of best practices of IM, and quality
improvement. PRIMIER is listed in the Registry of Regis-
tries (RoPR ID: 40), which is maintained by AHRQ and
ClinicalTrials.gov (NCT01754038). The intent is that PRI-
MIER will continue to expand over time, including more
publicly-funded as well as private IM centers with ever in-
creasing data which could be used for the mentioned objec-
tives. At present, PRIMIER is 2 years into an anticipated
10-year study timeframe. Active enrolling sites are ex-
pected to grow significantly beyond the present 14
recruiting centers.
Research setting and eligibility criteria
As of June 30, 2015, the BraveNet PBRN includes the 14
member sites listed in Table 1 as well as the BraveNet
Data and Statistical Coordinating Center. Most of our
sites are specialty care, integrative medicine clinics, al-
though an increasing number of member clinics have pri-
mary care capacities. The study is open to any patient age
18 or over who is seen by a provider for clinical purposes
Table 1 BraveNet Member Clinics (as of 6/30/2015)
Site Location
Alliance Institute for Integrative Medicine Cincinnati, OH
Boston Medical Center at Boston University Boston, MA
Center for Integrative Medicine at University of Maryland School of Medicine Baltimore, MA
Duke Integrative Medicine at Duke University Durham, NC
Integrative Medicine at the University of Colorado Denver Denver, CO
Jefferson-Myrna Brind Center for Integrative Medicine at Thomas Jefferson Medical College Philadelphia, PA
Mount Sinai Beth Israel Center for Health and Healing New York, NY
Osher Center for Integrative Medicine at Northwestern University Chicago, IL
Osher Center for Integrative Medicine at University of California, San Francisco San Francisco, CA
Osher Center for Integrative Medicine at Vanderbilt University Nashville, TN
Penny George Institute for Health and Healing at Allina Health Minneapolis, MN
Scripps Center for Integrative Medicine at Scripps Health La Jolla, CA
Simms/Mann Health and Wellness Center, Program in Integrative Medicine at Venice Family Clinic Los Angeles, CA
University of Pittsburgh Center for Integrative Medicine Pittsburgh, PA
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able to provide informed consent, to participate, and to be
contacted in the future by study personnel. Patients who
are involved only in an education program or one-time ac-
tivity are excluded from participation.
Ethics, consent and permissions
All participants will be asked to provide informed consent
before initiation of any study-related procedures. The
protocol was approved by the Institutional Review Board
at each participating site including Beth Israel Medical
Center Human Subjects Protection Office Institutional
Review Board; Boston University Medical Center Institu-
tional Review Board; Colorado Multiple Institutional Re-
view Board; Duke University Health Systems Institutional
Review Board; Northwestern University Institutional Re-
view Board; Schulman Associates Institutional Review
Board; Scripps Clinic Institutional Review Board; Thomas
Jefferson University Division of Human Subjects Protec-
tion; University of California Los Angeles Institutional
Review Board; University of California San Francisco
Committee on Human Research; University of Maryland
Institutional Review Board; University of Maryland Insti-
tutional Review Board and Vanderbilt University Human
Research Protection Program. In addition, the Einstein
Human Research Protection Program and Duke Univer-
sity Health Systems Institutional Review Board approved
the study as the BraveNet Data and Statistical Coordinat-
ing Center. The study is registered in Clinical Trials.gov
(NCT01754038).
Screening procedures and enrollment
Potential participants receive PRIMIER enrollment infor-
mation either from clinic or research staff. Patients whodecide to participate in PRIMIER log onto the PRIMIER
website and electronically enroll directly into the regis-
try. Online registrants are able to provide informed con-
sent upon opening the first screen on their initial visit to
the website. If they do not have computer access or are
uncomfortable with technology, patients may provide
informed consent and complete the survey questionnaire
by pen and paper. Following enrollment in PRIMIER,
PRO measures are obtained at 2-month intervals for the
first 6 months, then every 6 months through the end of
year two. This information is combined with data extracted
from the participants’ EHR. We anticipate approximately
10,000 participants to be enrolled in PRIMIER.
Data collection
PRIMIER currently uses the Research Electronic Data
Capture (REDCap) system as an online research man-
agement tool to collect patient reported data. REDCap is
a secure, web-based application designed exclusively to
support data capture for research studies [12]. REDCap,
which was initiated with funding from the National Insti-
tutes of Health, allows researchers to create study-specific
websites for capturing participant data securely through
an intuitive interface for users to enter data and have real
time validation rules (with automated data type and range
checks) at the time of entry. REDCap further allows
automated data export procedures for seamless data
downloads to Excel, SPSS, SAS, and Stata. Developed
by Vanderbilt University, REDCap currently supports 994
academic/non-profit consortium partners and over 100,000
research end-users (http://project-redcap.org). From Au-
gust 2013 to May 2015, PRIMIER patient surveys were
collected using the Patient Reported Outcomes Measure-
ment Information System (PROMIS) Assessment Center at
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REDCap in May 2015 to give the BraveNet coordinating
center (Albert Einstein College of Medicine) the ability to
modify the survey and create one registry database instead
of maintaining individual site databases as had been neces-
sary with the Assessment Center platform.
Data collection schedule
With the exception of the tobacco and alcohol use ques-
tionnaires and EHR data, all other data measures are
collected seven times: at baseline and at two, four, six, 12,
18, and 24 months. Tobacco and alcohol use are asked at
baseline, 12, and 24 months, and medical record data are
pulled at baseline and every 6 months. See Table 2 for the
schedule of data collection, and the following Demograph-
ics, Outcome Measures, and Utilization/Intervention Data
sections for more detail.
Demographics
PRIMIER participants are asked to answer 19 items relat-
ing to basic demographics: age, race, ethnicity, sex, educa-
tion, marital, employment and insurance status, likelihood
of insurance billing, household income, and self-reported
height and weight. Lifestyle behaviors such as alcohol and
tobacco use, nutrition and exercise habits, and use of opi-
oid medication are also asked of all participants. These
questions, shown in the Additional file 1, are not scored
and will be treated categorically in data analyses.
Patient-reported outcome measures
PRIMIER uses the PROMIS-29 instrument as the core
PRO measure along with the Perceived Stress Scale-4 (PSS-
4) [13] and the Patient Activation Measure (PAM) [14].
Created with funding from the National Institutes of
Health, the PROMIS suite of PRO instruments provides
clinicians and researchers access to efficient, valid, and
responsive self-reported measures of health, including
symptoms, function, and well-being. The PROMIS-29
instrument includes four-item short forms covering seven
distinct domains including physical function, anxiety, de-
pression, fatigue, pain intensity and pain interference,
satisfaction with social role, as well as sleep disturbance.
Questions are answered using standard one through five
Likert scales. The PROMIS-29 has been validated as per-
forming as well as a variety of legacy PRO measures [15],
and the four-item subscales for depression and anxiety
have been found to have good internal reliability among
chronic pain patients [16]. A crosswalk has been devel-
oped and validated between PROMIS Pain Interference
and the Pain Interference subscale of the Brief Pain Inven-
tory [17], and between the PROMIS Fatigue short form
and the Modified Fatigue Impact Scale [18]. PROMIS De-
pression has also been cross-walked with several common
depression measures (e.g., Beck Depression Inventory-IIand Center for Epidemiologic Study-Depression) [19]. In
addition to the PROMIS-29, we include one PROMIS
question to assess global quality of life.
The Perceived Stress Scale-4 (PSS-4) is a brief, validated,
and widely used psychological instrument for assessing a
participant’s perception of stress level. Based on an ori-
ginal 14-item scale [20], the PSS-4 consists of four ques-
tions to measure the degree to which participants perceive
situations in their lives as stressful [13]. It includes ques-
tions related to perceived unpredictability, uncontrollabil-
ity, and overload. This short version is recommended for a
brief assessment when respondent time is limited. Partici-
pants choose responses ranging from never (0) to very
often (4) with a total score ranging from 0 to 16. A recent
study on the PSS-4 reconfirms its reliability [21].
The Patient Activation Measure (PAM) is a brief, vali-
dated instrument for gauging the knowledge, skills and
confidence essential to managing one’s own health and
healthcare [14]. The 13-item PAM assessment (a short
form of the original 22-item instrument) [22] divides
participants into one of four progressively higher activa-
tion levels. Each level addresses a broad array of self-
care behaviors and offers insight into the characteristics
that drive health activation [22]. Positive changes in acti-
vation have been associated with positive changes in a
variety of self-management behaviors [23]. Improvement
in patient activation has been shown to be strongly related
to improvements in clinical outcomes such as decreased
pain, increased utilization of prevention screenings, and a
reduction in emergency room visits [23]. The four levels
are defined as: Level 1 – Does not believe that he/she has
an active or important role; Level 2 – Lacks confidence
and knowledge to take action; Level 3 – Beginning to
take action; and Level 4 – Maintaining behavior over
time. The PAM has been used in several studies of IM
interventions [24–26].
Utilization/intervention data
In addition to providing PRO measures, participants
report the primary condition(s) or symptom(s) for which
they are receiving treatment and the type of IM practi-
tioner from whom they are receiving care based on
questions from the National Health Interview Survey. At
each data collection point, patients are asked to rate or
describe their change in symptoms, etc. since beginning
care at the IM clinic [27]. Patients report whether they
are experiencing chronic pain, defined as 4 or greater on
an 11-point visual analog scale. PRIMIER also collects
information on what IM interventions patients have uti-
lized in the past 6 months. Utilization of IM treatments
is captured through two methods: 1) as reported by the
study participants using patient visit questionnaires;
and 2) as reported by the sites through an electronic
or paper medical record extraction process. Each site
Table 2 Outcome Measures Utilized in PRIMIER
Measure Frequency
Demographics Baseline 2 months 4 months 6 months 12 months 18 months 24 months
Age ● ● ● ● ● ● ●
Race ● ● ● ● ● ● ●
Ethnicity ● ● ● ● ● ● ●
Sex ● ● ● ● ● ● ●
Education ● ● ● ● ● ● ●
Marital status ● ● ● ● ● ● ●
Employment status ● ● ● ● ● ● ●
Insurance status ● ● ● ● ● ● ●
Likelihood of insurance billing ● ● ● ● ● ● ●
Household income ● ● ● ● ● ● ●
Self-reported height ● ● ● ● ● ● ●
Self-reported weight ● ● ● ● ● ● ●
Opioid medication use ● ● ● ● ● ● ●
Fruit and vegetable Intake ● ● ● ● ● ● ●
Tobacco and alcohol use ● ● ●
Exercise ● ● ● ● ● ● ●
Patient-Reported Outcome Measures
PROMIS-29 ● ● ● ● ● ● ●
PROMIS-1 (Quality of Life) ● ● ● ● ● ● ●
Perceived Stress Scale (PSS-4) ● ● ● ● ● ● ●
Patient Activation Measure (PAM) ● ● ● ● ● ● ●
Utilization/Intervention
Patient Self-Report
Experience with IM services ● ● ● ● ● ● ●
IM service utilization ● ● ● ● ● ● ●
Chronic pain ● ● ● ● ● ● ●
Primary condition being treated ● ● ● ● ● ● ●
Primary symptom being treated ● ● ● ● ● ● ●
Change in symptoms ● ● ● ● ● ● ●
Medical Records
IM Clinic Visits
Dates of all appointments to the IM clinic ● ● ● ●
IM services received ● ● ● ●
Diagnostic codes (ICD-9) ● ● ● ●
Billing codes (CPT) ● ● ● ●
Any Clinic Visit
Height ● ● ● ●
Weight ● ● ● ●
Pain ● ● ● ●
Lipid Panels ● ● ● ●
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electronic medical and administrative records: dates of all
appointments to the IM clinic, IM services received,diagnostic codes (International Classification of Diseases-
9: ICD-9) associated with each IM visit, and billing codes
(Current Procedural Terminology: CPT) associated with
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to the BraveNet data coordinating center. Additional data
fields will be added from patient visits to any clinic (i.e.,
not limited to IM clinic visits) as relevant to specific




All subjects who complete baseline measurements, ≥1
follow-up visit at a BraveNet clinic, and who are followed
for at least 6 months in the study will be included in stat-
istical analyses. Counts and percentages will be reported
on categorical variables whereas continuous variables will
be expressed as means and standard deviations (SDs)
and/or medians (25th and 75th percentiles). The Wilcoxon
rank-sum test or Chi-square test (Fisher’s exact as
appropriate) will be used to quantify comparisons as
deemed necessary.
Future data analysis
In observational studies like PRIMIER, there is no treat-
ment randomization. Therefore, to minimize the effects
of potential stable moderators (e.g., sex), channeling bias,
and/or time- varying confounders, a Marginal Structural
Model (MSM) approach will be utilized to analyze the
final PRIMIER database. An MSM analysis is a weighted
repeated measures approach using IM modality as a time-
varying covariate as well as accounting for baseline char-
acteristics. Weights produce a pseudo-population with a
balance in both time-invariant and time-varying covari-
ates, allowing for causal treatment comparisons using
standard repeated measures models. The weighting will
also be adjusted to account for missing data, providing
validity under missing at random or missing completely at
random. In order to incorporate adjustment for patients
with missing visits, the same weight approach is used.
However, instead of using a flag to designate IM modality,
a flag denoting whether the patient remained in the study
is used. The final weight for each patient’s observation
is computed by multiplying the IM modality selection
weights and the censoring weights. There are four major
components which need to be computed/assessed to per-
form a MSM analysis: 1) weight estimates for each subject
visit adjusting for IM modality, 2) weight estimates for
each subject visit adjusting for study discontinuation,
3) an a priori chosen vector of time-independent variables,
such as baseline characteristics, 4) an a priori chosen IM
modality or set of IM modalities which will be assigned as
the “treatment of interest” and tracked throughout time.
Adjusted mean outcomes by study time as well as result-
ing F-test p-values will be reported by outcome measure.
As our sample size increases and the proportion of
those completing long term follow-up assessments grows,we will be able to evaluate the impact of IM on pain
scores in subgroups including but not limited to: sex, BMI
< 30 vs BMI ≥ 30, and <40 on the PROMIS Depression
Subscale vs ≥40 on PROMIS Depression Subscale. The
potential of the varying impacts of IM on subgroups will
be assessed by including interaction terms, i.e., subgroup
by IM, in the MSM model. In the case that the interaction
terms are statistically significant, separate MSM analyses
will be performed within each subgroup. Also, the weight
estimates for each subject visit will be computed adjusting
for dose of modality or modalities of interest (e.g., acu-
puncture or IM physician visit) instead of IM modality in
the MSM analysis. Accounting for modality dosing by visit
over the course of the study may potentially create more
robust weight estimates for each subject by providing
more information than just a binary response variable.
Sensitivity analysis to assess the impact of retention
rate will be performed on pre-specified subgroups of
subjects who completed:
 75 % of surveys over the study period
 50 % of surveys over the study period
 25 % of surveys over the study period
All analyses will be conducted using SAS (Cary, NC).Discussion
The BraveNet PBRN has the potential to provide valuable
information regarding the benefits of IM in real world
settings. The PRIMIER project is already demonstrating
changes in PRO measures in participants receiving care at
our collaborating clinical sites. At this early stage, the
initial PRIMIER cohort contributing a full 6 months of
data is not large enough to accurately assess which inter-
ventions or which combination of interventions have had
the greatest effect on PAM scores, depression and stress
scores, or other PROs. Nor is there yet the ability to dis-
cern which IM interventions are most effective at improv-
ing symptoms in specific clinical populations receiving
care at the BraveNet clinics. However, as participation and
the retention rate increase, we will be able to refine our
analysis and further examine which modalities or combi-
nations thereof are most effective. For example, we will be
able to address the question of which IM approaches are
most effective in treating pain, which is by far the most
common reason that patients seek care at our clinics
[28–30]. Moreover, what is the optimal dosing of acu-
puncture for specific cancer conditions or does elevated
depressive symptomology influence the effectiveness of
mind/body interventions in patients with physical ail-
ments? As the PRIMIER database grows and with in-
creased demographic diversity provided by additional
future sites, BraveNet is well-poised to address some of
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The goal of PRIMIER is to create a registry of suffi-
cient size so that we can explore subsequent hypotheses.
For example, we may hypothesize that pain patients who
receive acupuncture weekly for 8 weeks would have
significantly improved outcomes on the PROMIS-29
measures at 12 months than pain patients who receive
acupuncture less frequently than weekly. Another example
of a hypothesis to be tested would compare the cohort of
patients with baseline elevated depressive symptomol-
ogy (<40 on the PROMIS Depression Subscale) vs non-
depressive symptomology (>40 on PROMIS Depression)
on Patient Activation Measure at 12 months.
From our prior mapping study of IM in the United
States [31], and from a BraveNet Registry study [28–30],
we learned that IM center leaders across the country
perceived that their interventions were most useful in
patients with complaints of chronic pain, depression, and
stress. In a different study of patients with a chief com-
plaint of chronic pain seen at the BraveNet sites, we previ-
ously reported that an IM approach to pain not only
decreased pain, but depressive symptomology and stress
as well [29]. Both of these studies were limited by virtue of
either one-time only assessment [28–30] or small sample
size [29]. From a more mature PRIMIER dataset, we
should be able to ascertain which particular treatment
modalities offer the greatest reduction in pain, as well as
changes on measures of depressive symptomology and
stress as examples.
The PRIMIER project offers a unique opportunity to
assess the effectiveness of IM clinic intervention in a
wide variety of clinical conditions. As the dataset grows
and the duration of follow-up increases, we expect to be
able to derive preliminary information to develop specific
research proposals to address the difficult- to-treat condi-
tions for which patients seek our care.
Given the rapid increase in the number of clinical set-
tings offering IM services, the public is continuing to seek
out these therapies to augment and integrate with conven-
tional medical practices. While randomized controlled
trials assess the efficacy of specific interventions for spe-
cific patient populations in “controlled settings”, observa-
tional studies evaluate the effectiveness of treatments in
the real world of clinical practice. The highly individ-
ualized nature of IM interventions also can make the
randomized controlled trials model problematic, since
treatments often evolve over time as a function of a given
individual’s response to treatment. Although there is now
a growing body of randomized controlled trial research on
the efficacy of integrative medicine approaches for a var-
iety of conditions [32–38], in many ways this body of
research does not accurately describe the real world prac-
tice of IM because of the controlled nature of the clinicaltrial paradigm. In contrast, observational research designs,
despite some inherent limitations, present a promising
option. Bell et al. suggest that observational designs are
appropriate for studying complex interventions, despite
the absence of randomization [2].
Treatment approaches consisting of multiple modalities
or components present unique challenges. In their 2014
protocol of an IM primary care trial, Herman and col-
leagues provide a useful overview of how truly integrative
approaches to care (as opposed to single-modality offerings)
can be described as complex interventions [39, 40]. These
complex interventions present challenges of “unpacking”,
due to the wide range of potential treatment combinations
and patient diagnoses [39]. Currently, we do not know
what the makeup of the population for PRIMIER will be
(i.e., what conditions and comorbidities patients will have
and what combinations of therapies they might receive).
For example, as in the Registry study [28], we may see a
higher proportion of patients with pain as compared with
other symptoms. Because our initial goal is to establish a
registry from which to conduct subsequent research, a key
feature of the project is that we are not driving the inter-
ventions or the population characteristics; rather, that
makeup is clinically driven. Therefore, our work is subject
to some limitations, from the standpoint of conventional
health outcomes research.
Authors of other multimodal studies have cited limita-
tions such as the inability to determine the relative efficacy
of components in a multifaceted study or intervention,
[11, 39] noting that the most beneficial elements of a
intervention may vary from patient to patient depending
on individual needs and personal characteristics [41]. Bell
argues that treatments that combine modalities (conven-
tional and/or complementary) should be studied in com-
bination as well [2]. Herman notes that larger effect sizes
may be achieved in more controlled settings [39]; however,
this is a tradeoff for studying a heterogeneous patient
population receiving individualized, sometimes complex
care. Maiers et al. acknowledge the limited generalizability
of an integrative care plan for low back pain, while
also pointing out how the adaptability of integrative care
models can make them more generalizable in some re-
spects [10]. While data from individual PRIMIER sites
may be similarly limited in their generalizability, the inclu-
sion of sites and patient populations from around the
country will provide a larger and more diverse sample
than comparable studies to date.
Although we recognize the importance of including
economic analyses in studies of IM, not all of the med-
ical costs for enrolled patients’ care will be available to
the extracts from our electronic health record (e.g., if a
patient received care at an emergency department out-
side the study site health system). Every effort will be
made to conduct appropriate health economic analyses
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other limitations in our analyses will be discussed in future
reporting of the study results. Notwithstanding, observa-
tional research using PROs will uniquely enable us to
describe the results of this type of individualized and dy-
namic care [42].
The exploration of IM in real-world settings is consistent
with the strategic plan of the National Institutes of Health,
National Center for Complementary and Integrative Health
(formerly the National Center for Complementary and
Alternative Medicine). Specifically, by seeking to “increase
understanding of ‘real world’ patterns and outcomes of
[complementary and alternative medicine] use and its
integration into health care and health promotion”,
[43] PRIMIER will serve as a national platform for fu-
ture evaluations of IM best practices. In providing the
means to begin determining these best practices, the
BraveNet PBRN will be able to define the most effective
IM interventions in a timely fashion, making valuable in-
formation readily available that will help guide patients,
providers, and payors to improve health and well-being
for all.
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